Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials

PLoS ONE

Volumn 4, Issue 3, 2009, Pages

  Merabishvili, Maya ^a,b,g   Pirnay, Jean Paul ^b   Verbeken, Gilbert ^b   Chanishvili, Nina ^a   Tediashvili, Marina ^a   Lashkhi, Nino ^a   Glonti, Thea ^a   Krylov, Victor ^c   Mast, Jan ^d   Van Parys, Luc ^b   Lavigne, Rob ^e   Volckaert, Guido ^e   Mattheus, Wesley ^e   Verween, Gunther ^b   De Corte, Peter ^b   Rose, Thomas ^b   Jennes, Serge ^b   Zizi, Martin ^b,f   De Vos, Daniel ^b   Vaneechoutte, Mario ^g  

^a George Eliava Institute of Bacteriophage Microbiology and Virology   (Georgia)

^b QUEEN ASTRID MILITARY HOSPITAL   (Belgium)

^c STATE RESEARCH INSTITUTE OF GENETICS AND SELECTION OF INDUSTRIAL MICROORGANISMS   (Russian Federation)

^d VETERINARY AND AGROCHEMICAL RESEARCH CENTRE   (Belgium)

^e LABORATORY OF GENE TECHNOLOGY   (Belgium)

^f VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^g GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ENDOTOXIN; PYROGEN; PROTEOME;

ARTICLE; BACTERIAL STRAIN; CONFORMATION; CYTOTOXICITY; DRUG FORMULATION; DRUG PURIFICATION; DRUG SCREENING; DRUG STABILITY; GENOME ANALYSIS; HUMAN; MOLECULAR INTERACTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEOMICS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PHAGE; QUALITY CONTROL; SHELF LIFE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS PHAGE; WOUND INFECTION; BACTERIOPHAGE; BURN; CLINICAL TRIAL; EVALUATION; GENETICS; METABOLISM; MICROBIOLOGY; PSEUDOMONAS INFECTION; STAPHYLOCOCCUS INFECTION; ULTRASTRUCTURE; VIROLOGY; VIRUS GENOME;

MYOVIRIDAE; PODOVIRIDAE; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

BACTERIOPHAGES; BURNS; CLINICAL TRIALS AS TOPIC; GENOME, VIRAL; HUMANS; PROTEOME; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; WOUND INFECTION;

EID: 64049105821     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004944     Document Type: Article

References (40)

1. Altoparlak U, Erol S, Ackay MN, Celebi F, Kadanali A (2004) The time-related changes of antimicrobial resistance patterns and predominant bacterial profiles of burn wounds and body flora of burned patients. Burns 30: 660-664.
2. Church D, Elsayed S, Reid O, Winston B, Lindsay R (2006) Burn wound infections. Clin Microbiol Rev 19: 403-434.
3. Pirnay J-P, De Vos D, Cochez C, Bilocq F, Pirson J, et al. (2003) Molecular epidemiology of Pseudomonas aeruginosa colonization in a burn unit: persistence of a multidrug-resistant clone and a silver sulfadiazine-resistant clone. J Clin Microbiol 41: 1192-1202.
4. d'Hérelle F (1917) Sur un microbe invisible antagoniste des bacilles dysentériques. Acad Sci Ser D: 165, 373.
5. Levy SB, Marschal B (2004) Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 10: S112-S129.
6. Brüssow H (2007) Phage therapy: the Western perspective. In: McGrath S, van Sinderen D, eds. Bacteriophage Genetics and Molecular Biology. Norfolk: Caister Academic Press. pp 159-192.
7. Chanishvili N, Chanishvili T, Tediashvili M, Barrow PA (2001) Phages and their application against drug-resistant bacteria. J Chem Technol Biotechnol 76: 689-699.
8. Górski A, Borysowski J, Miedzybrodzki R, Weber-Dabrowska B (2007) Bacteriophages in medicine. In: Mc Grath S, van Sinderen D, eds. Bacteriophage Genetics and Molecular Biology. Norfolk: Caister Academic Press. pp 126-158.
9. Krylov VN (2001) Phage therapy in terms of bacteriophage genetics: hopes, prospects, safety, limitations. Russian J Genetics 37: 869-887.
10. Merril CR, Scholl D, Adhya SL (2003) The prospect for bacteriophage therapy in Western medicine. Nat Rev Drug Discov 2: 489-497.
11. Sulakvelidze A, Kutter E (2005) Bacteriophage therapy in humans. In: Kutter E, Sulakvelidze A, eds. Bacteriophages: Biology and Applications. Boca Raton: CRC Press. pp 381-436.
12. Calendar R, Abedon S, eds (2006) The bacteriophages. Oxford: Oxford Univ Press. 746p.
13. Villareal LP (2005) Overall issues of virus and host evolution. In: Villareal LP, ed. Viruses and the Evolution of Life. Washington: ASM Press. pp 1-28.
14. Verbeken G, De Vos D, Vaneechoutte M, Merabishvili M, Zizi M, et al. (2007) European regulatory conundrum of phage therapy. Future Microbiol 2: 485-491.
15. Babalova EG, Katsitadze KT, Sakvarelidze LA, Imniashvili NS, Sharashidze TG, et al. (1968) Preventive value of dried dysentery bacteriophage. Zh Mikrobiol Epidemiol Immunobiol 2: 143-145.
16. Biswas B, Adhya S, Washart P, Paul B, Trostel AN, et al. (2002) Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect Immun 70: 204-210.
17. Bruttin A, Brüssow H (2005) Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother 49: 2874-2878.
18. Capparelli R, Ventimiglia I, Roperto S, Fenizia D, Iannelli D (2005) Selection of an Escherichia coli O157:H7 bacteriophage for persistence in the circulatory system of mice infected experimentally. Clin Microbiol Infection 12: 248-253.
19. Chibani-Chennoufi S, Sidoti J, Brüttin A, Kutter E, Sarket, et al. (2004) In vitro and in vivo bacteriolytic activities of Escherichia coli phages: implications for phage therapy. Antimicrob Agents Chemother 48: 2558-2569.
20. McVay CS, Velasquez M, Fralick JA (2007) Phage therapy of Pseudomonas aeruginosa infections in a mouse burn wound model. Antimicrob Agents Chemother 51: 1934-1938.
21. Smith HW, Huggins MB (1982) Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J Gen Microbiol 128: 307-318.
22. Smith HW, Huggins MB (1983) Effectiveness of phage treatment in experimental Escherichia coli diarrhoea in calves, piglets and lambs. J Gen Microbiol 129: 2659-2675.
23. Smith HW, Huggins MB, Shaw KM (1987) The control of experimental Escherichia coli diarrhoea in calves by means of bacteriophages. J Gen Microbiol 133: 1111-1126.
24. Soothill JS (1992) Treatment of experimental infection of mice with bacteriophages. J Med Microbiol 37: 258-261.
25. Watanabe R, Matsumoto T, Sano G, Ishii Y, Tateda K, et al. (2007) Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob Agents Chemother 51: 446-452.
26. Wills QF, Kerrigan C, Soothill JS (2005) Experimental bacteriophage protection against Staphylococcus aureus abscess in a rabbit model. Antimicrob Agents Chemother 49: 1220-1221.
27. Adams MH (1959) Assay of phages by the agar layer method. In: Adams MH, ed. Bacteriophages. New York: Interscience Publishers. pp 450-451.
28. Carlson K (2005) Methodological Approaches. In: Kutter E, Sulakvelidze A, eds. Bacteriophages: Biology and Applications. Boca Raton: CRC Press. pp 437-490.
29. Imberechts H, Wild P, Charlier G, De Greve H, Lintermans P, et al. (1996) Characterization of F18 fimbrial genes fedE and fedF involved in adhesion and length of enterotoxemic Escherichia coli strain 107/86. Microb Pathog 21: 183-192.
30. Miller RV (1998) Methods for enumeration and characterization of bacteriophages from environmental samples. In: Burlage RS, Atlas R, Stahl D, Geesey G, Sayer GS, eds. Techniques in Microbial Ecology. New York: Oxford University Press. pp 218-235.
31. Kwan T, Liu J, DuBow M, Gros P, Pelletier J (2006) Comparative genomic analysis of 18 Pseudomonas aeruginosa bacteriophages. J Bacteriol 188: 1184-1187.
32. Ceyssens PJ, Lavigne R, Mattheus W, Chibeu A, Hertveldt K, et al. (2006) Genomic analysis of Pseudomonas aeruginosa phages LKD16 and LKA1: establishment of the phiKMV subgroup within the T7 supergroup. J Bacteriol 188: 6924-6931.
33. Lavigne R, Burkal'tseva MV, Robben J, Sykilinda NN, Kurochkina LP, et al. (2003) The genome of bacteriophage phiKMV, a T7-like virus infecting Pseudomonas aeruginosa. Virology 312: 49-59.
34. O'Flaherty S, Coffey A, Edwards R, Meaney W, Fitzgerald GF, et al. (2004) Genome of staphylococcal phage K: a new lineage of Myoviridae infecting gram-positive bacteria with a low G+C content. J Bacteriol 186: 2862-2871.
35. Gill JJ, Pacour JC, Carson ME, Leslie KE, Griffiths MW, et al. (2006) Efficacy and pharmacokinetics of bacteriophage therapy in treatment of subclinical Staphylococcus aureus mastitis in lactating dairy cattle. Antimicrob Agents Chemother 50: 2912-2918.
36. Perez-Cappelano R, Manelli JC, Palayret D, Carlin G, Echinard C, et al. (1976) Evaluation of the septicaemic risk by a quantitative study of the cutaneous flora in patients with burns. Burns 3: 42-45.
37. Boratynski JD, Syper D, Weber-Dabrowska B, Kusiak-Szelachowska M, Pozniak G, et al. (2004) Preparation of endotoxin-free bacteriophages. Cell Mol Biol Lett 9: 253-259.
38. Kerby GP, Gowdy RA, Dillon ES, Dillon ML, Csaky TZ, et al. (1949) Purification, pH stability and sedimentation properties of the T7 bacteriophage of Escherichia coli. J Immunol 63: 93-107.
39. Schneider LA, Korber A, Grabbe S, Dissemond J (2007) Influence of pH on wound-healing: a new perspective for wound-therapy. Arch Dermatol Res 298: 413-420.
40. Merabishvili M, Verhelst R, Glonti T, Chanishvili N, Krylov V, et al. (2007) Digitized fluorescent RFLP analysis (fRFLP) as a universal method for comparing genomes of culturable dsDNA viruses: application to bacteriophages. Res Microbiol 158: 572-581.